Mathias Romacker
Independent Device Strategy Consultant

About

Mathias Romacker is an independent device strategy consultant. He has also served as a Kymanox Executive Advisor (KEA) since 2022.

Mr Romacker has than 30 years of experience in the field of injectable drug delivery devices. He brings a deep understanding of prefilled syringes, handheld injection devices and on-body wearable devices, having been involved in multiple successful combination product launches.

He was Senior Director, Device Strategy at Pfizer Headquarters in New York City, until late 2019 having joined the company in March 2015. In this commercial role he focused on the front end of device technology. He worked with multiple functions and sites across the organisation to develop a device strategy for Pfizer pipeline and inline products. Previously he worked for more than nine years in the device area for Amgen. Before joining Amgen he held multiple sales and marketing positions with BD and Gerresheimer in Germany, South Africa and New Jersey, US.

Mr Romacker was a co-chair for the PDA Universe of Pre-filled Syringes and Injection Devices in 2013, 2017, 2019 and 2022, and received the PDA Edward Smith Packaging Science Award in 2018 for his contributions over the years. He holds a Masters equivalent degree in Economics from the University of Freiburg, Germany.

Contributions

ROUNDTABLE

ROUNDTABLE: DISCUSSION ON ANTI-OBESITY TREATMENTS

Stephen M Perry, Mathias Romacker and Andreas Schneider tackle the subject of GLP-1s and related obesity-targeted injectable therapeutics and the enormous impact they are having and are expected still to have on drug delivery and the wider pharmaceutical sector.

More contributions

INTERVIEW

Interview: Kymanox Executive Advisors Mathias Romacker, Fran DeGrazio & Paul Jansen

Mathias Romacker, Fran DeGrazio and Paul Jansen sit down with Guy Furness, to discuss what it is that has driven Kymanox’s rapid rise in the drug delivery space and what makes the consulting company’s model so successful, as well as to share their expertise on a variety of topics in an illuminating discussion, including connectivity, how large and small drug developers engage with consultancies, 5 mL autoinjectors and the interface between drug primary packaging and delivery devices.

INTERVIEW

MATHIAS ROMACKER, PFIZER

Mathias Romacker shares his thoughts on the emergence of connectivity in drug delivery devices, he explains why he thinks the buzz around connectivity in delivery systems is more than just hype and describes the trends in the pharma sector that mean it makes sense now to connect up devices.